Investigational Drug
Investigational drug that reduces hepcidin offers promise for treating anemia
LONG BEACH, Calif. — Researchers reported results from a phase 1b/2a placebo-controlled study of DISC-0974, an anti-hemojuvelin antibody to treat anemia in patients with chronic kidney disease.
Investigational two-drug regimen safe, effective for patients with HIV
DENVER — Phase 2 study data showed that a once-weekly oral regimen of an investigational two-drug HIV treatment was well tolerated among patients with HIV and allowed them to maintain viral suppression.
Evenamide boosts symptom improvement in treatment-resistant schizophrenia
Evenamide, an investigational drug for treatment-resistant schizophrenia, was linked with “increasing, sustained and clinically significant” symptom improvements in a recent study, according to a manufacturer press release.
FDA allows higher dose of investigational drug in study of children with Dravet syndrome
Stoke Therapeutics Inc. announced the FDA will allow administration of a higher single dose of its investigational drug STK-001 in its ongoing phase 1/2a MONARCH study of children and adolescents with Dravet syndrome.
FDA grants IND clearance to Transcenta for IgA nephropathy treatment
The FDA granted investigational new drug clearance to Transcenta Holding Limited for TST004, its humanized monoclonal antibody that attacks the enzyme contributing to IgA nephropathy development, according to a press release.
FDA approves IND application for CBD-based opioid use disorder treatment
The FDA has granted investigational drug designation to Ananda Scientific Inc. for Nantheia ATL5, a liquid augmentative cannabidiol-based treatment for opioid use disorder, according to a company press release.